文献速递临床试验与 GCP流行病学与生物统计

复杂临床试验的监管审评:Paul-Ehrlich-Institut科学建议程序系统综述

The use of complex clinical trials: a regulatory review.
PubMed 文献 · Trials · 2026-04-09

该研究系统综述了Paul-Ehrlich-Institut职责范围内产品的科学建议程序,识别出30项科学建议程序对应29项不同的复杂临床试验。结果显示申请人提出的复杂试验设计数量不断增加,监管关注点与传统试验设计基本一致,但需逐案审慎考虑,早期与监管机构沟通对试验成功设计与实施至关重要。

要点

  • 复杂临床试验设计提案数量呈增加趋势。
  • 探索性试验中多臂导致的多重性控制缺失通常可被接受,前提是队列可视为独立。
  • 需预先规划新增治疗臂、适当多重性控制及对照组定义。

核心结论

  • 监管对复杂试验的关注点与传统试验设计基本一致,但复杂性要求逐案审慎考虑。
  • 早期与监管机构沟通对复杂临床试验的成功设计与实施至关重要。

研究设计与样本

  • 系统综述,审查Paul-Ehrlich-Institut职责范围内产品的科学建议程序。
  • 共识别30项科学建议程序,对应29项不同的复杂临床试验。

主要发现

  • 申请人提出的复杂试验设计数量不断增加。
  • 探索性试验中多臂导致的多重性控制缺失通常被监管接受,前提是队列可视为独立。
  • 申请人频繁提出使用共同对照组。

关键数值与推荐

  • 多重性控制缺失在探索性试验中通常可接受,条件为队列可视为独立。

临床怎么用

  • 复杂临床试验应预先规划新增治疗臂、适当多重性控制及对照组定义。
  • 建议早期与监管机构沟通以确保试验成功设计与实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Complex clinical trials offer flexibility in evaluating multiple treatments or diseases simultaneously. These trials often feature adaptive designs, common controls, and the potential to add new arms. However, the increased complexity raises methodological challenges particularly regarding multiple testing or the adequate choice of control groups. Despite guidance from regulatory bodies like the European Medicines Agency and the U.S. Food and Drug Administration, uncertainties remain about the regulatory acceptance of these trials. METHODS: This systematic review examines scientific advice procedures of products in the remit of the Paul-Ehrlich-Institut for complex clinical trials to highlight key concerns and regulatory feedback. We identified 30 scientific advice procedures corresponding to 29 different complex clinical trials. RESULTS: Our findings reveal an increasing number of complex trial designs proposed by applicants. A lack of multiplicity control due to multiple arms was generally considered acceptable by regulators in exploratory trials and if cohorts can be considered independent. Additionally, the use of common control groups is frequently proposed by applicants. The review underscores the importance of pre-planning for new treatment arms, appropriate multiplicity control, and the definition of control groups in trial designs. CONCLUSION: Overall, our findings suggest that regulatory concerns regarding complex trials largely align with those in traditional trial designs, though their complexity requires careful, case-by-case consideration. Early engagement with regulatory agencies can be crucial to ensure the successful design and implementation of these trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nguyen Q, Kästel H, Hees K, et al. The use of complex clinical trials: a regulatory review. Trials. 2026. PMID: 41957650. doi:10.1186/s13063-026-09674-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。